Nokia Retains Neutral and 3 Stock Analyses to Eye
Incyte Corporation (NASDAQ:INCY): After Incyte Corporation and Eli Lilly (NYSE:LLY) reported Phase IIb results for their Baricitinib in Rheumatoid Arthritis, Oppenheimer expects the drug to be approved in 2015-2016. The firm thinks the Baricitinib program is going well and they keep a $23 price target and Outperform rating on Incyte.
Nokia Corporation (NYSE:NOK): Citigroup said their checks in Europe and North America found that Nokia Corporation’s recently-launched Lumia phones are selling fairly well with several stores noting they were sold out after receiving very small amounts. Given the negative investor sentiment, Citi said that their checks are much more positive than anticipated. The firm keeps a Neutral rating on their stock.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Best Buy Co. Inc. (NYSE:BBY): Oppenheimer believes that Best Buy Co. Inc.’s latest strategy does not aggressively take care of the two things that have hurt the company’s results in recent years: price competition from online retailers and an ineffective store infrastructure. The firm maintains a Perform rating on Best buy.
Hub Group Inc. (NASDAQ:HUBG): As previously reported, Baird raised the status on Hub Group Inc. from Neutral to Outperform. This upgrade was based on expectations that gross margin pressures will ease secular domestic inter modal growth and valuation. Their price target is $38.
Don’t Miss: Are the iPad’s Days of Glory Numbered?